Comparative evaluation of measles, mumps & rubella vaccine at 9 & 15 months of age.

Simple item page
dc.contributor.authorYadav, Sangitaen_US
dc.contributor.authorThukral, Richaen_US
dc.contributor.authorChakarvarti, Anitaen_US
dc.date.accessioned2003-11-16en_US
dc.date.accessioned2009-05-27T08:15:43Z
dc.date.available2003-11-16en_US
dc.date.available2009-05-27T08:15:43Z
dc.date.issued2003-11-16en_US
dc.description.abstractBACKGROUND & OBJECTIVES: Measles, mumps and rubella (MMR) contribute to significant amount of mortality and morbidity in our country. Though MMR vaccine has been a part of immunization schedule in the developed countries, it is yet to be included in our national immunization schedule. Hence this study was conducted to assess the serological status of measles, mumps and rubella in young children and to evaluate the seroconversion of measles, mumps and rubella vaccine at 9 and 15 months of age. METHODS: The cohort study was carried out at the out patient department of a tertiary care hospital in north India. A total of 240 normal children, 120 each in the age group 9-10 and 15-18 months attending the hospital for immunization were enrolled for the study. None of them had been vaccinated with MMR vaccine in the past, or gave any history of measles, mumps or rubella infection, or were on any immunosuppressive agent. The pre-vaccination blood sample was taken and each child was administered a single dose of trivalent MMR vaccine. The post-vaccination sample was taken 6-8 wk later. The paired serum samples were analysed for the presence of measles, mumps and rubella antibodies using commercially available ELISA kits. RESULTS: Of the 120 infants in the age group of 9-10 months, 102 (85%) were seronegative for measles and 96 (80%) were seronegative for both mumps and rubella. Following MMR vaccination, 102 infants came for post vaccination sampling of which 92 per cent were seropositive for measles, 100 per cent for mumps and 98 per cent for rubella. In the age group of 15-18 months, of the 120 children, 67 (56%) were seronegative for measles, 84 (70%) for mumps and 86 (71.6%) for rubella. In 50 per cent of the children, there was a history of measles immunization at 9 months of age. After MMR vaccination, 100 children came for post vaccination sampling and seropositivity of 92, 96 and 94 per cent was observed for measles, mumps and rubella, respectively. The rise in the pre- and post-immunization geometrical mean titre was significant (P < 0.05) for each component of the vaccine in both the age groups. INTERPRETATION & CONCLUSION: The MMR vaccine can be offered safely and with equal efficacy to children at 9 and 15 months of age.en_US
dc.description.affiliationDepartment of Paediatrics, Maulana Azad Medical College, New Delhi, India. Sangita_yadav@hotmail.comen_US
dc.identifier.citationYadav S, Thukral R, Chakarvarti A. Comparative evaluation of measles, mumps & rubella vaccine at 9 & 15 months of age. Indian Journal of Medical Research. 2003 Nov; 118(): 183-6en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/23820
dc.language.isoengen_US
dc.source.urihttps://icmr.nic.in/ijmr/ijmr.htmen_US
dc.subject.meshAge Factorsen_US
dc.subject.meshCohort Studiesen_US
dc.subject.meshHumansen_US
dc.subject.meshIndiaen_US
dc.subject.meshInfanten_US
dc.subject.meshMeasles-Mumps-Rubella Vaccine --administration & dosageen_US
dc.titleComparative evaluation of measles, mumps & rubella vaccine at 9 & 15 months of age.en_US
dc.typeClinical Trialen_US
dc.typeComparative Studyen_US
dc.typeJournal Articleen_US
dc.typeResearch Support, Non-U.S. Gov'ten_US
Files
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.79 KB
Format:
Plain Text
Description:
Download
Collections
Indian Journal of Medical Research